Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 7Thoracic 6Gastrointestinal 5Genitourinary 4Lymphoid 3Tumor-Agnostic 2Gynecologic 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1Breast 1

Conditions

Neoplasms, Unknown Primary 1Neoplasms 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × antineoplaston A10 × Tumor-Agnostic × Clear all
NCT00003526 2020-12-17

Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin

Burzynski Research Institute

Phase 2 Terminated
8 enrolled 5 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00003494 2018-01-31

Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

Burzynski Research Institute

Phase 2 Terminated
4 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡